FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022754087> ?p ?o ?g. }

• W2022754087 endingPage "411" @default.
• W2022754087 startingPage "405" @default.
• W2022754087 abstract "This multicenter randomized phase III study was designed to compare the efficacy and toxicity of IFN alpha-2c (3.5 MU/d) in combination with either araC (10 mg/m(2) d1-10) or hydroxyurea (HU: 25 mg/kg per day) in newly diagnosed CML patients. A total of 114 patients were randomized. Following a median observation period of 36 (range 1-73) months the major cytogenetic response rates were 25 and 27% and the 4-year survival probabilities 62.5 and 63% for the araC and HU group, respectively. While the overall toxicity profile was comparable between both groups, patients in the HU arm exhibited a slightly higher degree of WHO grades 3 and 4 non-hematological toxicities." @default.
• W2022754087 created "2016-06-24" @default.
• W2022754087 creator A5002055787 @default.
• W2022754087 creator A5005056139 @default.
• W2022754087 creator A5008313136 @default.
• W2022754087 creator A5009138600 @default.
• W2022754087 creator A5012577746 @default.
• W2022754087 creator A5019003637 @default.
• W2022754087 creator A5022912841 @default.
• W2022754087 creator A5024651241 @default.
• W2022754087 creator A5025757739 @default.
• W2022754087 creator A5027381686 @default.
• W2022754087 creator A5028913166 @default.
• W2022754087 creator A5032509163 @default.
• W2022754087 creator A5036755760 @default.
• W2022754087 creator A5039285562 @default.
• W2022754087 creator A5039994927 @default.
• W2022754087 creator A5040912167 @default.
• W2022754087 creator A5041797055 @default.
• W2022754087 creator A5046642228 @default.
• W2022754087 creator A5050118017 @default.
• W2022754087 creator A5060733373 @default.
• W2022754087 creator A5061264691 @default.
• W2022754087 creator A5067806282 @default.
• W2022754087 creator A5069486775 @default.
• W2022754087 creator A5085447243 @default.
• W2022754087 creator A5087125819 @default.
• W2022754087 creator A5088571921 @default.
• W2022754087 date "2003-05-01" @default.
• W2022754087 modified "2023-10-06" @default.
• W2022754087 title "A randomized study comparing interferon (IFNα) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)" @default.
• W2022754087 cites W1704878397 @default.
• W2022754087 cites W188630774 @default.
• W2022754087 cites W1928548710 @default.
• W2022754087 cites W2007182999 @default.
• W2022754087 cites W2010012100 @default.
• W2022754087 cites W2038990138 @default.
• W2022754087 cites W2058190985 @default.
• W2022754087 cites W2089716717 @default.
• W2022754087 cites W2122797075 @default.
• W2022754087 cites W2337277825 @default.
• W2022754087 cites W2508058084 @default.
• W2022754087 cites W977069352 @default.
• W2022754087 doi "https://doi.org/10.1016/s0145-2126(02)00223-0" @default.
• W2022754087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12620292" @default.
• W2022754087 hasPublicationYear "2003" @default.
• W2022754087 type Work @default.
• W2022754087 sameAs 2022754087 @default.
• W2022754087 citedByCount "22" @default.
• W2022754087 countsByYear W20227540872012 @default.
• W2022754087 countsByYear W20227540872013 @default.
• W2022754087 countsByYear W20227540872017 @default.
• W2022754087 countsByYear W20227540872019 @default.
• W2022754087 countsByYear W20227540872021 @default.
• W2022754087 crossrefType "journal-article" @default.
• W2022754087 hasAuthorship W2022754087A5002055787 @default.
• W2022754087 hasAuthorship W2022754087A5005056139 @default.
• W2022754087 hasAuthorship W2022754087A5008313136 @default.
• W2022754087 hasAuthorship W2022754087A5009138600 @default.
• W2022754087 hasAuthorship W2022754087A5012577746 @default.
• W2022754087 hasAuthorship W2022754087A5019003637 @default.
• W2022754087 hasAuthorship W2022754087A5022912841 @default.
• W2022754087 hasAuthorship W2022754087A5024651241 @default.
• W2022754087 hasAuthorship W2022754087A5025757739 @default.
• W2022754087 hasAuthorship W2022754087A5027381686 @default.
• W2022754087 hasAuthorship W2022754087A5028913166 @default.
• W2022754087 hasAuthorship W2022754087A5032509163 @default.
• W2022754087 hasAuthorship W2022754087A5036755760 @default.
• W2022754087 hasAuthorship W2022754087A5039285562 @default.
• W2022754087 hasAuthorship W2022754087A5039994927 @default.
• W2022754087 hasAuthorship W2022754087A5040912167 @default.
• W2022754087 hasAuthorship W2022754087A5041797055 @default.
• W2022754087 hasAuthorship W2022754087A5046642228 @default.
• W2022754087 hasAuthorship W2022754087A5050118017 @default.
• W2022754087 hasAuthorship W2022754087A5060733373 @default.
• W2022754087 hasAuthorship W2022754087A5061264691 @default.
• W2022754087 hasAuthorship W2022754087A5067806282 @default.
• W2022754087 hasAuthorship W2022754087A5069486775 @default.
• W2022754087 hasAuthorship W2022754087A5085447243 @default.
• W2022754087 hasAuthorship W2022754087A5087125819 @default.
• W2022754087 hasAuthorship W2022754087A5088571921 @default.
• W2022754087 hasConcept C126322002 @default.
• W2022754087 hasConcept C168563851 @default.
• W2022754087 hasConcept C203014093 @default.
• W2022754087 hasConcept C2776178377 @default.
• W2022754087 hasConcept C2778041864 @default.
• W2022754087 hasConcept C2778729363 @default.
• W2022754087 hasConcept C2909179924 @default.
• W2022754087 hasConcept C29730261 @default.
• W2022754087 hasConcept C31760486 @default.
• W2022754087 hasConcept C71924100 @default.
• W2022754087 hasConcept C90924648 @default.
• W2022754087 hasConceptScore W2022754087C126322002 @default.
• W2022754087 hasConceptScore W2022754087C168563851 @default.
• W2022754087 hasConceptScore W2022754087C203014093 @default.
• W2022754087 hasConceptScore W2022754087C2776178377 @default.
• W2022754087 hasConceptScore W2022754087C2778041864 @default.
• W2022754087 hasConceptScore W2022754087C2778729363 @default.

• next